Utilizing Neuroplasticity for the Treatment of MDD Symptoms
Major Depressive Disorder (MDD) affects millions of people, and many continue to experience symptoms even after initiating treatment.¹˒²      Please join us as we explore the need for new therapeutic options for MDD, discuss often-overlooked symptoms, and discuss how dysfunctional neural circuits may contribute to those symptoms. Leading MDD experts will also introduce and review Rejoyn, an innovative therapeutic approach designed to target the brain regions affected by MDD and leverage the brain’s innate neuroplasticity to adjust neural connections that may alleviate MDD symptoms.³˒⁴

Rejoyn delivers a unique combination of cognitive-emotional training exercises, cognitive behavioral therapy-based video lessons, and supportive text messages through a smartphone application. This approach was evaluated in the Mirai Clinical Trial, which you can learn more about by attending this program.

This program will equip you to make informed decisions about whether Rejoyn is an appropriate treatment option for your patients with MDD. You will also learn how to incorporate Rejoyn into your practice and support patients in their treatment journey.

Key reasons to attend

  • Gain insight into the need for innovative treatment options for MDD
  • Discover Rejoyn, an adjunctive treatment option for MDD symptoms in adult patients who are on antidepressant medication
  • Explore the clinical evidence supporting the efficacy and safety of Rejoyn
  • Learn how to prescribe Rejoyn and augment your patient’s MDD treatment with a therapy that was shown to have no side effects related to Rejoyn in the pivotal clinical trial
  • Participate in a live Q&A session and get expert answers to your questions

Stay tuned for upcoming events in 2025!

We’re excited to bring you engaging speaker programs starting in 2025. Please check back soon for updates and event details. In the meantime, feel free to explore our resources at https://www.rejoynhcp.com/ or request to connect with an MSL for more information.
References:
1. National Institute of Mental Health. Major Depression. July 2023. Accessed June 3, 2024. https://www.nimh.nih.gov/health/statistics/major-depression
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
3. Otsuka and Click Therapeutics announce the U.S. Food and Drug Administration (FDA) clearance of Rejoyn™, the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms. Press release. April 1, 2024. Accessed July 30, 2024. https://www.otsuka-us.com/news/rejoyn-fda-authorized
4. Iacoviello BM, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety. 2014;31:699-706.
This program is concluded.

 

 

 

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.